Journal of Clinical Case Reports

Xiaoshi Zhang

Publications

• Case Report
  Seroconversion of Hbsag in Melanoma Patient with Hepatitis B Treated with Checkpoint Inhibitors: A Case Report
  Author(s): Xizhi Wen, Ya Ding, Baoyan Zhu, Dandan Li, Jinjin Li, Yao Wang and Xiaoshi ZhangXizhi Wen, Ya Ding, Baoyan Zhu, Dandan Li, Jinjin Li, Yao Wang and Xiaoshi Zhang
  
  Based on remarkable and sustained antitumor activity, the anti-CTLA-4 antibody ipilimumab, and anti-PD1 antibodies nivolumab and pembrolizumab have been approved for treatment of advanced melanoma. As checkpoint blockade is associated with potentially serious immune-related adverse events, including autoimmune hepatitis, clinical trials evaluating these agents have excluded patients with chronic hepatitis B virus infection. Herein, we describe one patient with advanced melanoma and concomitant HBV infections experiencing seroconversion of HBsAg after treatment with combination of PD-1 and CTLA-4 blockade. .. Read More»
  DOI: 10.4172/2165-7920.1000951

  Abstract PDF